Janssen Search
Search results
Updated Phase 2 CAPTIVATE study results demonstrate sustained clinical benefit of fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax as first-line treatment for patients with chronic lymphocytic leukaemia, including those with high-risk disease
Jun 14, 2024 At 5 years, 67 percent of patients were progression-free, with overall survival at 96 percent for all treated patients 1 BEERSE, BELGIUM (14 June 2024) – Janssen-Cilag International NV, a Johnson & Johnson company, today announced updated ...
Johnson & Johnson submits application to the European Medicines Agency for DARZALEX® (daratumumab)-based quadruplet therapy for the treatment of patients with transplant-eligible, newly diagnosed multiple myeloma
Mar 06, 2024 Belgium Submission supported by data from Phase 3 PERSEUS study, which showed the daratumumab subcutaneous formulation-based regimen significantly reduced the risk of progression or death, compared to standard of care regimen. [1] BEERSE, ...
Crucell
Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February 2011. For information on our organization please visit the Janssen Infectious Diseases and Vaccines website. For information on Crucell vaccines and contact details, ...
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy
Jul 26, 2024 Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib 1, 2, 3, 4 In the MARIPOSA-2 study, ...
Janssen Presents Longer-Term Talquetamab Follow-Up Data Showing Overall Response Rates of More Than 70 Percent in Heavily Pretreated Patients with Multiple Myeloma
Jun 03, 2023 United States Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX FASPRO ® combination biweekly regimen showed an overall response rate of more than 80 percent CHICAGO, June 3, 2023 – The Janssen ...
European Commission approves RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy
Aug 27, 2024 Belgium Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, have until now faced a poor prognosis and limited treatment options after disease progression on an EGFR TKI [1], [2], [3], [4] Amivantamab ...
Investigational targeted oral peptide JNJ-2113 demonstrated positive results in moderate-to-severe plaque psoriasis in Phase 2b study published in New England Journal of Medicine
Feb 07, 2024 United States Data from FRONTIER 1, a Phase 2b clinical trial, show JNJ-2113, the first and only targeted oral peptide that selectively blocks the IL-23 receptor, achieved the primary and all secondary endpoints including PASI a 100 and IGA b ...
European Commission approves BALVERSA®▼ (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma
Aug 23, 2024 Belgium First pan FGFR kinase inhibitor to be approved in the European Economic Area, for adults with unresectable or metastatic urothelial carcinoma and susceptible FGFR 3 alterations Approval based on THOR results, showing 36 percent ...
Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor Receptor Alterations Treated with BALVERSA® (erdafitinib) Vs Chemotherapy
Oct 21, 2023 Spain Data from Cohort 1 of the Phase 2 THOR-2 study showed oral erdafitinib reduced the risk of disease recurrence or death compared with intravesical standard-of-care chemotherapy MADRID, Spain, October 21, 2023 – The Janssen Pharmaceutical ...
Health Canada Authorizes IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination with Venetoclax for Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Mar 24, 2023 Canada All-oral, once-daily, fixed-duration combination regimen authorized for first-line treatment of CLL TORONTO, March 23, 2023- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a ...